STOCK TITAN

ALX Oncology Holdings Inc. - $ALXO STOCK NEWS

Welcome to our dedicated page for ALX Oncology Holdings news (Ticker: $ALXO), a resource for investors and traders seeking the latest updates and insights on ALX Oncology Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALX Oncology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALX Oncology Holdings's position in the market.

Rhea-AI Summary

ALX Oncology reported positive financial results for the first quarter of 2024 and provided a corporate update. The company achieved significant milestones in its clinical trials, including positive data in various cancer treatments. They also announced key appointments and upcoming milestones for their pipeline. Financially, ALX Oncology reported cash, cash equivalents, and investments of $184.5 million as of March 31, 2024, with additional funding secured through an ATM offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
-
Rhea-AI Summary

ALX Oncology Holdings Inc. announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer. With her extensive experience in oncology product development, she is expected to drive the growth of the company during a promising period. The company is focused on developing therapies that target the CD47 immune checkpoint pathway, with upcoming clinical study readouts for evorpacept. Dr. Dillon's background in commercial strategy and portfolio development positions ALX Oncology for further success in the oncology market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
management
-
Rhea-AI Summary

ALX Oncology announced the initiation of a Phase 2 Investigator-Sponsored Trial of neoadjuvant radiation and evorpacept in combination with pembrolizumab for patients with untreated HPV-mediated oropharyngeal cancer. The trial aims to address the need for novel therapies in this patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
ALX Oncology announces the acceptance of two abstracts for poster presentation at the 2024 ASCO Annual Meeting. The abstracts focus on Evorpacept in combination with other therapies for urothelial carcinoma and colorectal cancer. ALX Oncology continues its immuno-oncology developments targeting the CD47 immune checkpoint pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
-
Rhea-AI Summary
ALX Oncology Holdings Inc. reported positive financial results for Q4 2023 and full year 2023, with a focus on evorpacept's success in the ASPEN-06 Phase 2 clinical trial. The company highlighted key findings, including a 52% overall response rate in the evorpacept combination treatment arm. ALX Oncology also executed a successful public offering generating $63.2 million in gross proceeds. The company anticipates significant clinical milestones in 2024 across various cancer types. Financially, the company ended 2023 with $218.1 million in cash, sufficient to fund operations into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
Rhea-AI Summary
ALX Oncology Holdings Inc. announces acceptance of two clinical abstracts for presentation at the AACR Annual Meeting. The abstracts focus on trials in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and higher-risk myelodysplastic syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
ALX Oncology Holdings Inc. (ALXO) to present at the 42nd Annual J.P. Morgan Healthcare Conference. CEO Jason Lettmann will provide a company overview on January 8th, 2024, at 4:30 PM PST. A live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Summary
ALX Oncology Holdings Inc. (ALXO) reported financial results for Q3 2023 and provided a corporate update. They achieved positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept, completed a public offering, realigned leadership, and advanced their pipeline of programs. The company also reported a strong financial position with $196.4 million in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
Rhea-AI Summary
ALX Oncology Holdings Inc. will participate in three upcoming investor conferences in November. The conferences include the 2023 UBS BioPharma Conference on November 8th in Miami Beach, FL, the 2023 Jefferies London Healthcare Conference on November 14th in London, UK, and the 2023 Piper Sandler Healthcare Conference on November 28th in New York, NY. Webcast links will be available on ALX Oncology's website for those who want to access the fireside chats.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
none
ALX Oncology Holdings Inc.

Nasdaq:ALXO

ALXO Rankings

ALXO Stock Data

654.38M
22.30M
2.67%
97.6%
6.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About ALXO

alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com